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Radiofrequency ablationAbstract Introduction: Surgical and locoregional therapies are different options in HCC treat-
ment, several locoregional techniques are used.
Purpose: This study aimed to assess the effectiveness of transarterial chemoembolization (TACE),
radiofrequency ablation (RFA) and combined therapy, in HCC management.
Materials and methods: The study was conducted at our University Hospital, from August 2011 to
February 2013. It included 60 patients with HCC (40 males and 20 females, age ranged between 45
and 70 years). Patients were classiﬁed into 3 groups, group 1 treated with TACE, group 2 with
RFA, and group 3 with both techniques. Response was assessed by triphasic CT and alpha fetopro-
tein. Patients were classiﬁed into good and poor responders after one and six months and one year.
Patients’ survival and incidence of recurrence were recorded.
Results: The percentage of good responders was greater with combined therapy than with TACE and
RFA (90%, 70%, and 60% respectively). The overall survival was 75% and the recurrence free survival
was 60% in TACE, 90%, and 45% in RFA and 95% and 90% in combined therapy respectively.
Conclusion: Combined therapy is superior regarding good response, overall survival, and free recur-
rence survival than either TACE or RFA alone.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND  license.e 71111,
ail.com
Table 1 HCC patients’ response by triphasic CT after TACE,
RFA, and combined therapy.
Group TACE RFA Combined therapy
n= 20 n= 20 n= 20
Good response 14 (70%) 12 (60%) 18 (90%)
Poor response 6 (30%) 8 (40%) 2 (10%)
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Management of HCC continuously presents many challenges
(1). It had been reported that surgical resection considered being
the best treatment for early stage HCC. However, only 9–29%
of HCC patients are candidates for surgery owing to either
underlying chronic liver diseases resulting in poor hepatic reserve
or multifocal distribution of the tumor (2). So, the locoregional
therapies including radiofrequency ablation (RFA), transarterial
chemoembolization (TACE) and others are now the current util-
ities for management of unresectable HCC (1).
Although TACE or RFA has proved that each of them im-
proves the survival rate deﬁnitely (3), however, each of them
having its practical constraints and limitations regarding the
tumor size, its location and efﬁcacy of the procedure.
It had been reported that combining RFA and TACE can
theoretically overcome the limitation of each when used alone
(3,4).
Reviewing studies concerning that issue, there were no sin-
gle three arms study that could be reached, comparing TACE,
RFA and combined therapy. Many studies either deal with
individual TACE and RFA or two arms study comparing
combined therapy with either TACE or RFA alone. In this
study, we have investigated the comparison of TACE, RFA
and combined therapy, as a three arms study; in treatment
of HCC as regards their efﬁcacy and patients’ survival.
2. Materials and methods
Sixty patients with HCC on top of liver cirrhosis (40 males and
20 females), their mean age 49 years (range 45–70 years), were
included in this 3 arms study. The study was conducted be-
tween August 2011 to February 2013 in the South Egypt can-
cer Institute and Assiut University Hospital. The protocol of
the study has been approved by the ethics committee of re-
search of Faculty of Medicine, Assiut University, and in-
formed written consent of the patients has been taken before
the study.
Patients were selected on the basis of clinical assessment, li-
ver function tests, abdominal US and triphasic helical CT of
the liver with scanning of the whole body to rule out extrahe-
patic metastasis. The inclusion criteria were:
1- Single hepatic focal lesion with size ranging between 5
and 7 cm. (A special 7 cm needle was used to treat these
large tumors by RFA).
2- Child-Pough class A or B (25 patients class A, and 35
patients class B).
3- High serum alpha fetoprotein (AFP) ranging from 200
to 400 ng/ml (mean 230).
4- Characteristic CT enhancement criteria of HCC (in arte-
rial, portal venous and delayed phases).
5- Platelet count more than 70,000/mm3.
Exclusion criteria
1- Evidence of exrahepatic metastasis.
2- Presence of portal vein or inferior vena cava thrombosis,
or biliary duct invasion.
3- Severe liver cirrhosis with Child-Pough class C.4- Severe coagulation disorders (prothrombin concentra-
tion less than 60% and platelet count less than 70,000/
mm3).
5- Presence of uncontrollable ascites.
Patients were classiﬁed into 3 matched groups each in-
cluded 20 patients. Group 1 patients were treated by TACE.
In group 2, RFA was done using RITA RF 1500X system
USA, and star burst XLi enhanced with tubing set (electrosur-
gical device). While, in group 3 combined therapy (TACE–
RFA) was performed (TACE was carried out ﬁrst followed
by RFA one week later). Chemotherapy used in this study con-
sisted of a mixture of Doxorubicin 50 mg dissolved in 10 cc sal-
ine mixed with 8 cc lipidol, 5 cc contrast media (ultravist
300 ml/cc), and gel foam. This dose was ﬁxed for all patients
regardless to body surface area due to the superselective injec-
tion of the mixture at the tumor feeding artery.
Therapeutic efﬁcacy was assessed and classiﬁed into good
responders, and poor responders. In cases of RFA this de-
pended on the basis of the size of the hypo attenuating non
enhancing area, and the lipidol uptake of the tumor in cases
of TACE according to Wang et al. (5).
Follow up from the time of treatment for a period of one
year could be achieved for all patients. The incidence of recur-
rence, development of new focal lesion, presence of progressive
disease or stable disease, as well as, survival in months was re-
corded for each patient. Triphasic CT and US (with the same
parameters as pretreatment scanning) were performed one
month after the procedure, 6 months, and one year later. In
addition, serum AFP was estimated before and one month at
the same intervals (one month, 6 months and one year) after
ablation.
3. Results
3.1. Group 1 (TACE)
This group included 20 patients for whom TACE was done.
Twelve patients showed good response (Excellent lipidol up-
take with no enhancing residual tumor tissue in triphasic
CT). Eight patients showed poor response (residual enhancing
tumor tissue) for whom another procedure was done one
month later. Two out of the 8 patients showed good response.
So, collectively 14/20 patients (70%) showed good response
and 6/20 patients (30%) showed poor response (Table 1).
AFP in patients who showed good response (14/20) is reduced
by 20–35% (the best reduction is by 35% and the least reduc-
tion was 20%) in all patients after one month. Moreover, at
6 months and one year follow up periods, AFP was in near
normal range. However, it was raised in patients who showed
Table 2 Follow up of HCC patients with good response after 1 year of TACE, RFA, and combined therapy.
TACE N= 14 RFA N= 12 Combined therapy N= 18
Recurrence disease (RD) 1 1 –
Recurrence with new focal lesions 1 2 –
Progressive disease (PD) – – –
Progressive disease with new focal lesion. – – –
Stable disease (SD) 12 9 18
Table 3 Follow up of HCC patients with poor response after 1 year of TACE, RFA, and combined therapy.
TACE n= 6 RFA n= 8 Combined therapy n= 2
Recurrence disease (RD) – – –
Recurrence with new focal lesions – – –
Progressive disease (PD) 2 2 1
Progressive disease with new focal lesion 3 4 –
Stable disease (SD) 1 2 1
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was detected in two patients (2/14) who demonstrated good re-
sponse after the 2nd session of TACE, and one of them devel-
oped new focal lesion. One of those patients showed re-raising
of the AFP but it did not change in the other patient. While 3/6
patients who demonstrated poor response, developed new fo-
cal lesion and had progression of primary tumor size. Regard-
ing the other three patients with poor response, one of them
showed stable lesion and the other two showed progression
of the tumor only (Tables 2 and 3)(Figs. 1–3).Fig. 1 (A and B) Triphasic CT scan of the liver showing hepatic ma
Digital subtraction angiography showing hepatic mass lesion. (D) N
subtraction angiography post TACE showing disappearance of tumor
month after the last TACE, showing marked response to treatment w4. Survival analysis at one, six months, and one year follow up
All patients were alive up to 6 months, while 5/20 patients
(25%) died by the end of the 1st year. Those who showed poor
response (4 patients), and another patient who showed good
response after the 2nd session developed local recurrence with
a new focal lesion. Therefore, overall survival was 75% (15/20
patients) but the recurrence free survival was 60% (12 patients)
(Table 4).ss involving segment 8 in arterial (a) and delayed phases (b). (C)
o subtracted angiography after chemoembolization. (E) Digital
vascularity and Lipiodol uptake. (F) CT scan at the same level one
ith dense lipidol uptake.
Fig. 2 (A and B) Triphasic CT scan of the liver showing hepatic mass involving Lt hepatic lobe segment 3 in arterial phases (C) CT scan
at the same level one month after TACE, showing marked response to treatment. (D) CT scan at the same level six months after TACE,
showing reduced size with no residual enhancing tumor tissue. (E) CT scan at the same level one year after TACE, showing vanishing of
the focal lesion with no residual enhancing tumor tissue. (F and G) Digital subtraction angiography showing angiographic blush of
hepatic mass lesion.
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This group included 20 patients for whom RFA was done.
Nine patients showed good response (complete ablation with
no residual enhancing tumor tissue in triphasic CT). On the
other hand, 11 patients demonstrated poor response (residual
enhancing tumor tissue), for them another session was done
one month later. Three out of 11 patients showed good re-
sponse after the 2nd session. So, collectively 12/20 patients
(60%) showed good response, while 8/20 patients remained
with poor response (40%) (Table 1).
AFP decreased initially by about 40% in all patients with
good response at the 1st follow up (one month), but was near
the normal range 6 months later in those who showed good re-
sponse (12/20 patients).
Three patients among 12 who showed good response after
the 2nd session developed local recurrence with re-rising of
the AFP at the near end of the 1st year and two of them devel-
oped new focal lesion in addition. While 4 patients out of the 8
patients, who demonstrated poor response, developed new fo-
cal lesion in addition to the progression of the primary tumor.
Regarding the other 4/8 patients, two of them developed only
progression of the tumor while the other two showed stable le-
sion (Tables 2 and 3).
5. Survival analysis at one, six months, and one year follow up
All patients were alive up to 6 months, while 2 patients with
poor response died by the end of the 1st year. So the overall
survival was 90% (18/20 patients) but the disease free survival
was 45% (9/20 patients) (Table 4).5.1. Group 3 (combined TACE and RFA)
Twenty patients were included in this group for whom com-
bined therapy (TACE and RFA) was performed. Seventeen
patients showed good response, while 3 patients showed poor
response for whom another session of TACE and RFA has
been performed one month later. One patient among the three
showed good response. So, 18/20 patients (90%) demonstrated
good response in that group, while 2/20 patients showed poor
response (10%) (Table 1).
AFP decreased by 45% in all patients with good response
at the one month follow up and nearly normal by the end of
one year in patients who demonstrated good response (18/20
patients). Neither local recurrence nor new focal lesion had
been demonstrated in the 18 patients who developed good re-
sponse. On the other hand, one of the two patients who dem-
onstrated poor response showed stable disease, while the other
had progressive disease and died (Tables 2 and 3).
6. Survival analysis at one, six months, and one year follow up
All patients were alive at the end of the 1st year except for one
patient who died (who demonstrated poor response). So, the
overall survival was 95% (19/20 patients) while the recurrence
free survival is 90% (18/20 patients) (Table 4). The single pa-
tient who survived out of the two who demonstrated poor re-
sponse showed stable lesion.
Complications were minor in the three groups and included
pain, nausea, and mild hyperthermia and these could be man-
aged conservatively. However there was one patient in the
group of RFA who developed minimal pneumothorax which







Overall survival 75 90 95
Recurrence free survival 60 45 90
Fig. 3 Right hepatic lobe HCC, pretreatment triphasic CT in arterial (a) and late phase (b). (c) Angiography before TACE. (d)
Angiography after TACE complete devascularization of the lesion. (e) US-guided electrode-needle insertion in the lesion and RF good
lipidol uptake with small peripheral lack of lipiodol. (g) Corresponding to some hypervascular tissue in the arterial phase (h), consisting of
very small residual tumor.
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bined therapy group with Child-Pough II, developed minimal
ascites but controlled with diuretics and salt free albumin.
7. Discussion
HCC is the third most important cause of cancer related mortal-
ity worldwide. Locoregional treatment options such as TACE
and RFA are minimally invasive treatment options that may
individually or in combination address the pertinent issue of suc-
cessful tumor targeting and preservation of liver function (6).
The current study is three arms one planned to compare
TACE, RFA and combined therapy with matched patients
groups.One year follow up of all patients could be achieved hardly
and with great effort reporting the response; the recurrence
(RD), the development of new focal lesion, the progression
(PD) and stable disease (SD), in addition the overall survival
and the recurrence free percentage in the three groups.
The percentage of good response was 70% in the TACE
group which is in accordance to the data of many other reports
(7–11), however it was higher than other reports (12). Mean-
while, it was 60% in the RFA group that was in the agreement
with other study (12). On the other hand, it was 90% in the
combined therapy group, and this goes with data of other
authors (13–15). Local recurrence (RD) and new focal lesion
were observed in 2 patients of the TACE group and 3 patients
of the RFA group, while neither recurrence nor new focal le-
sions was detected in the combined therapy group.
It was noticed that recurrence developed in patients who
needed 2nd session either of the TACE or RFA group.
Regarding patients who demonstrated poor response in the
three therapeutic modalities, 5 patients developed progression
of the disease (PD) and 1 patient showed stable disease (SD) in
the TACE group. Meanwhile, 6 patients developed PD and 2
patients showed SD in the RFA group. In the combined
400 M.H.M. Othman et al.therapy group, one of the two patients who demonstrated poor
response showed stable disease, while the other died.
In the TACE group the overall survival was 75%, while the
recurrence free survival was 60% and this goes with other pub-
lished data (16). On the other hand, the overall survival in
RFA group was 90%, while the free recurrence survival was
45% and this goes with the data of other reports (17–19).
Alternatively, in the combined therapy group the overall sur-
vival was 95%, while the free recurrence survival was 90%,
and this is in accordance with the data of other authors
(14,20). The results in other reports show decrease in the per-
centage of overall and free recurrence survivals (21,22).
From the previous data we can conclude that combined
therapy is superior regarding the good response, overall sur-
vival, and the free recurrence survival to either TACE or
RFA alone. This has been explained by Peng et al. (15) that
occlusion of hepatic arterial ﬂow by means of TACE before
RF ablation reduces the cooling effect of hepatic blood ﬂow
on thermal coagulation. Furthermore, lipidol and gelatin
sponge particles used in TACE reduce the portal ﬂow around
the tumor by ﬁlling the peripheral portal veins around the tu-
mor with lipidol via multiple arterio portal communications,
thus the necrotic area induced by RFA may be increased, in
addition to, the positive thermal impact on the anticancer ef-
fect of the retained chemotherapeutic agent. While TACE ther-
apy is relatively superior to RFA, one considering the
percentage of good response and the recurrence free survival
that is in accordance with other studies (23–26) which reported
that RFA is 100% effective in lesions not more than 3 cm,
while TACE is more suitable for larger lesions.
Regarding the alpha-fetoprotein, it was decreased gradually
near to the normal levels in all patients who developed good
response in the three groups, and this goes with data reported
by other authors (11,23).
In fact, the current study has three limitations. The ﬁrst is
small sample size relative to other studies. The second is short
period of follow up, which is one year only, and of course we
cannot predict the result data of each group on a longer follow
up. Thirdly the study was not blindly randomized to avoid
selection bias during evaluation of patients.
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